(Q43242011)

17 November 2017

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies (English)

1 reference

17 November 2017

Sender Herschorn

1

1 reference

17 November 2017

J Stephen Jones

2

1 reference

17 November 2017

Matthias Oelke

3

1 reference

17 November 2017

Scott MacDiarmid

4

1 reference

17 November 2017

Joseph T Wang

5

1 reference

17 November 2017

Zhonghong Guan

6

1 reference

17 November 2017

language of work or name

English

0 references

publication date

14 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

75

1 reference

17 November 2017

5

1 reference

17 November 2017

1149-1155

1 reference

Reviewing the ICS 2002 terminology report: The ongoing debate

17 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Prevalence and burden of overactive bladder in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Detrusor instability with equivocal obstruction: A predictor of unfavorable symptomatic outcomes after transurethral prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Impact of fesoterodine on quality of life: pooled data from two randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Fesoterodine dose response in subjects with overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Muscarinic receptor subtypes in human and rat colon smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

The International Continence Society “Benign Prostatic Hyperplasia” Study: The Bothersomeness of Urinary Symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

Do oral antimuscarinic drugs carry an increased risk of acute urinary retention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.007

10.1016/J.UROLOGY.2009.09.007

7 January 2021

Identifiers

DOI

1 reference

release_ausye4tmfzdrtouhvji3pux44u

17 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ausye4tmfzdrtouhvji3pux44u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference